Abbott Laboratories (ABT) News| Reuters.com
Edition:
United States

Abbott Laboratories (ABT)

ABT on New York Consolidated

37.91USD
24 Jun 2016
Change (% chg)

$-1.72 (-4.34%)
Prev Close
$39.63
Open
$38.37
Day's High
$38.56
Day's Low
$37.91
Volume
16,525,037
Avg. Vol
8,932,099
52-wk High
$51.74
52-wk Low
$36.00

Select another date:

Mon, Jun 13 2016

BRIEF-Abbott announces results from study of Freestyle Libre system for type 1 diabetes

* Abbott announces positive results from groundbreaking study of Freestyle Libre system for people with type 1 diabetes

BRIEF-Abbott sets quarterly dividend of $0.26/shr

* Sets quarterly dividend of $0.26 per share Source text for Eikon: Further company coverage:

BRIEF-Slate Retail REIT to acquire Abbott's village in Georgia

* Slate Retail REIT announces the purchase of Abbott's village in Georgia

BRIEF-Alere obtains requisite lender approval for extension to file Form 10

* Announces certain developments relating to the pending merger transaction with abbott laboratories

Abbott to buy St. Jude for $25 billion to boost heart devices

Abbott Laboratories said on Thursday that it would buy St. Jude Medical Inc in a $25 billion deal to expand its heart device business, but investors worried that the acquisition would not pay off as promised.

LPC: Abbott’s $17.2 billion loan backing St. Jude acquisition set to boost M&A volume

NEW YORK A US$17.2bn bridge loan that backs Abbott Laboratories’ US$25bn acquisition of medical device maker St. Jude Medical will boost investment grade loan volume that so far this year has been depressed by volatility in equities and global economic uncertainty.

Fitch Maintains Abbott on Rating Watch Negative

(The following statement was released by the rating agency) CHICAGO, April 28 (Fitch) Fitch Ratings has maintained Abbott Laboratories' (ABT, Abbott) 'A'/'F1' ratings on Rating Watch Negative. The rating action follows the announcement of Abbott's intention to acquire St. Jude Medical Inc. (STJ, St. Jude) and its previously announced agreement from February 2016 to acquire Alere Inc. (Alere). Fitch will resolve the Rating Watch as more details regarding the transactions become available. Ho

UPDATE 1-LPC: Abbott's US$17.2bn loan backing St. Jude acq. set to boost M&A volume

NEW YORK, April 28 A US$17.2bn bridge loan that backs Abbott Laboratories' US$25bn acquisition of medical device maker St. Jude Medical will boost investment grade loan volume that so far this year has been depressed by volatility in equities and global economic uncertainty.

LPC: Abbott's US$17.2bn loan backing St. Jude acq. set to boost M&A volume

NEW YORK, April 28 A US$17.2bn bridge loan that backs Abbott Laboratories' US$25bn acquisition of medical device maker St. Jude Medical will boost investment grade loan volume that so far this year has been depressed by volatility in equities and global economic uncertainty.

BRIEF-S&P- Abbott Laboratories ratings remain on creditwatch negative on planned acquisition of St. Jude

* Abbott Laboratories ratings remain on creditwatch negative on planned acquisition of St. Jude Medical Source text: (http://bit.ly/21hkyCp) (Bengaluru Newsroom +91 80 6749-1130; within U.S. +1 646 223 8780)

Select another date: